ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS

BACKGROUND: Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), and vorasidenib (AG-881, VOR) is an oral, potent, brain-penetrant inhibitor of mIDH1/2. Both have been evaluated in glioma patients in ongoing phase 1 studies. In orthotopic glioma m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mellinghoff, Ingo, Cloughesy, Timothy, Wen, Patrick, Taylor, Jennie, Maher, Elizabeth, Arrillaga-Romany, Isabel, Peters, Katherine, Choi, Changho, Ellingson, Benjamin, Lin, Alexander, Thakur, Sunitha, Nicolay, Brandon, Lu, Min, Le, Kha, Yin, Feng, Tai, Feng, Schoenfeld, Steven, S Pandya, Shuchi, Hassan, Islam, Steelman, Lori, Clarke, Jennifer
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847677/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados